OmniSpirant Therapeutics

Executive Summary

OmniSpirant Therapeutics is an Irish biotech company founded in 2020, developing first-in-class regenerative gene therapies for severe lung diseases via its proprietary OmniSome platform. This technology leverages engineered stem cell exosomes to enable efficient intracellular delivery of RNA and protein therapeutics through inhalation, addressing key challenges in targeting lung tissue. The company’s initial pipeline focuses on cystic fibrosis and lung cancer, areas with significant unmet medical needs and limited effective treatment options. As a private, early-stage company, OmniSpirant is poised to advance its platform through preclinical and potential clinical development, though it has not yet disclosed specific funding rounds or regulatory milestones. The platform’s novelty and potential for broad applicability in pulmonary diseases position it as a promising player in the regenerative medicine space, albeit at an early stage of validation.

Upcoming Catalysts (preview)

• TBDPreclinical proof-of-concept data for cystic fibrosis candidate20% success
• TBDIND filing for lead program15% success
• TBDPartnership or licensing deal for OmniSome platform10% success